TALTZ
Clinical safety rating: caution
Comprehensive clinical and safety monograph for TALTZ (TALTZ).
Ixekizumab is a humanized IgG4 monoclonal antibody that selectively binds to interleukin-17A (IL-17A) with high affinity and neutralizes its activity. IL-17A is a pro-inflammatory cytokine implicated in the pathogenesis of psoriasis, psoriatic arthritis, and ankylosing spondylitis. By inhibiting IL-17A, ixekizumab reduces inflammation and the downstream effects of IL-17A on keratinocytes, synoviocytes, and other cells.
| Metabolism | Ixekizumab is a monoclonal antibody, expected to be degraded into small peptides and amino acids via catabolic pathways, similar to endogenous IgG. No major hepatic metabolism; clearance via reticuloendothelial system. |
| Excretion | Taltz (ixekizumab) is a monoclonal antibody degraded into small peptides and amino acids via general protein catabolism. Renal excretion of intact drug is negligible; fecal excretion accounts for <5% of the dose. |
| Half-life | Terminal elimination half-life is approximately 26 days (range 20–30 days) in patients with plaque psoriasis. This supports monthly subcutaneous dosing. |
| Protein binding | Ixekizumab binds to human IgG4 and albumin; total protein binding is approximately 90–95%. |
| Volume of Distribution | Volume of distribution is approximately 7.5 L (0.11 L/kg for a 70 kg individual), indicating limited extravascular distribution and primarily confinement to the vascular space. |
| Bioavailability | Subcutaneous: Absolute bioavailability is approximately 80% (range 60–90%) following subcutaneous administration. |
| Onset of Action | Subcutaneous: Clinical improvement in psoriasis symptoms may be observed as early as 1–2 weeks after the first dose, with significant responses reported by week 4. |
| Duration of Action | Duration of therapeutic effect is approximately 4 weeks following a single subcutaneous dose, consistent with the dosing interval for maintenance therapy (every 4 weeks). |
Adults: 160 mg subcutaneously initially (Day 0), followed by 80 mg at Weeks 2, 4, 6, 8, 10, 12, then 80 mg every 4 weeks.
| Dosage form | INJECTABLE |
| Renal impairment | No dose adjustment required for renal impairment. |
| Liver impairment | No dose adjustment required for hepatic impairment. |
| Pediatric use | Not approved for pediatric use. |
| Geriatric use | No specific dose adjustment required; use caution due to higher infection risk. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for TALTZ (TALTZ).
| Breastfeeding | Unknown if excreted in human milk; M/P ratio not available. Endogenous IgG is present in breast milk. Consider developmental benefits of breastfeeding vs. potential for immune suppression in infant. |
| Teratogenic Risk | Insufficient human data; animal studies show no evidence of fetal harm. IgG1 antibodies cross placenta minimally in first trimester, increasing in second and third trimesters. Theoretical risk for fetal immune suppression; avoid live vaccines in infants up to 5 months post-maternal exposure. |
| Fetal Monitoring |
■ FDA Black Box Warning
There is no black box warning for TALTZ.
| Serious Effects |
["Serious hypersensitivity reaction to ixekizumab or any excipient"]
| Precautions | ["Serious infections: Do not administer during active infection. Monitor for signs of infection; discontinue if serious infection develops.","Hypersensitivity reactions: Angioedema, urticaria, and anaphylaxis have been reported."] |
Loading safety data…
| Monitor for maternal infections during therapy. No specific fetal monitoring required; assess fetal growth and development per routine prenatal care. |
| Fertility Effects | No data on human fertility effects. In animal studies, no impairment of fertility observed. |